Price alert —
Sign in to get a one-time email the moment GNPX crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · GNPX
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare GNPX vs peers
Line GNPX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with GNPX
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2025-05-12 | -286.00 | -451.00 | +36.6% | +2.2% |
| 2025-04-01 | 2.58 | -0.39 | +761.5% | +28.3% |
| 2024-11-13 | -1353.00 | -3003.00 | +55.0% | +2.5% |
| 2024-08-09 | -3300.00 | -2530.00 | -30.4% | -11.3% |
| 2024-05-15 | -4059.00 | -2794.00 | -45.3% | -3.4% |
| 2024-04-01 | -24299.02 | -6044.51 | -302.0% | -4.4% |
| 2023-03-31 | -6600.01 | -6600.01 | — | -3.3% |
| 2022-11-14 | -5720.01 | -5280.01 | -8.3% | -4.9% |
| 2022-08-12 | -4840.00 | -5280.01 | +8.3% | +18.1% |
| 2022-05-13 | -5280.01 | -5280.01 | — | -0.7% |
| 2022-03-30 | -5233.81 | -4840.00 | -8.1% | -1.7% |
| 2021-11-15 | -3080.00 | -4840.00 | +36.4% | -3.9% |
| 2021-08-13 | -3520.00 | -5720.01 | +38.5% | -4.7% |
| 2021-05-17 | -6160.01 | -5280.01 | -16.7% | — |
| 2020-11-12 | -3080.00 | -9240.01 | +66.7% | — |
| 2020-08-11 | -5280.01 | -8360.01 | +36.8% | — |
| 2020-05-14 | -8800.01 | -3520.00 | -150.0% | — |
| 2019-05-15 | -6160.01 | -9240.01 | +33.3% | — |
| 2019-04-01 | -10120.01 | -5280.01 | -91.7% | — |
| 2018-11-14 | -6600.01 | -5720.01 | -15.4% | — |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| GNPX ★ | $0B | — | -3.5 | — | — | 0.2 | — | — | — | -234.86% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 0.79%
| Holder | Shares | % out |
|---|---|---|
| Geode Capital Management, LLC | 1,517 | 0.30% |
| Mayflower Financial Advisors, LLC | 909 | 0.18% |
| Manchester Financial Inc | 909 | 0.18% |
| Vanguard Capital Management LLC | 270 | 0.05% |
| Cygnus Capital Advisors, LLC | 100 | 0.02% |
| Jones Financial Companies, L.L.L.P. | 96 | 0.02% |
| Citigroup Inc. | 93 | 0.02% |
| Cheviot Value Management, LLC | 45 | 0.01% |
| Sound Income Strategies, LLC | 45 | 0.01% |
| Osaic Holdings Inc. | 11 | — |
Insider activity · 90d
No insider trades for GNPX in last 90d.
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-14 | FORM 8-K | view · |
| 8-K | 2026-06-22 | FORM 8-K | view · |
| 8-K | 2026-06-18 | FORM 8-K | view · |
| 8-K | 2026-06-12 | FORM 8-K | view · |
| 8-K | 2026-05-26 | FORM 8-K | view · |
| 8-K | 2026-05-14 | FORM 8-K | view · |
| 10-Q | 2026-05-13 | FORM 10-Q | view · |
| 8-K | 2026-04-30 | FORM 8-K | view · |
| DEF 14A | 2026-04-29 | FORM DEF 14A | view · |
| 8-K | 2026-04-28 | FORM 8-K | view · |
| 8-K | 2026-04-21 | FORM 8-K | view · |
| 4 | 2026-04-15 | FORM 4 | view · |
| 10-K | 2026-03-30 | FORM 10-K | view · |
| 8-K | 2026-03-18 | FORM 8-K | view · |
| 4 | 2026-02-27 | FORM 4 | view · |
| 4 | 2026-02-27 | FORM 4 | view · |
| 8-K | 2026-02-23 | FORM 8-K | view · |
| 8-K | 2026-02-10 | FORM 8-K | view · |
| 8-K | 2026-01-09 | FORM 8-K | view · |
| 8-K | 2026-01-07 | FORM 8-K | view · |
| 8-K | 2026-01-06 | FORM 8-K | view · |
| 4 | 2025-12-23 | FORM 4 | view · |
| 4 | 2025-12-23 | FORM 4 | view · |
| 4 | 2025-12-23 | FORM 4 | view · |
| 4 | 2025-12-23 | FORM 4 | view · |
| 4 | 2025-12-23 | FORM 4 | view · |
| 8-K | 2025-12-23 | FORM 8-K | view · |
| 8-K | 2025-11-26 | FORM 8-K | view · |
| S-1 | 2025-11-21 | FORM S-1 | view · |
| 8-K | 2025-11-21 | FORM 8-K | view · |
| 8-K | 2025-11-19 | FORM 8-K | view · |
| 8-K | 2025-11-18 | FORM 8-K | view · |
| 10-Q | 2025-11-14 | FORM 10-Q | view · |
| 8-K | 2025-11-04 | FORM 8-K | view · |
| 8-K | 2025-10-29 | FORM 8-K | view · |
| 8-K | 2025-10-28 | FORM 8-K | view · |
| 8-K | 2025-10-24 | FORM 8-K | view · |
| 8-K | 2025-10-23 | FORM 8-K | view · |
| 8-K | 2025-10-21 | FORM 8-K | view · |
| 8-K | 2025-10-17 | FORM 8-K | view · |
| S-1 | 2025-09-12 | FORM S-1 | view · |
| 8-K | 2025-08-20 | FORM 8-K | view · |
| 8-K | 2025-08-18 | FORM 8-K | view · |
| 8-K | 2025-08-15 | FORM 8-K | view · |
| 10-Q | 2025-08-14 | FORM 10-Q | view · |
| 8-K | 2025-08-04 | FORM 8-K | view · |
| DEF 14A | 2025-07-16 | FORM DEF 14A | view · |
| 4 | 2025-07-01 | FORM 4 | view · |
| 4 | 2025-07-01 | FORM 4 | view · |
| 8-K | 2025-06-24 | FORM 8-K | view · |
| 8-K | 2025-06-23 | FORM 8-K | view · |
| S-1 | 2025-06-11 | FORM S-1 | view · |
| 8-K | 2025-06-11 | FORM 8-K | view · |
| 8-K | 2025-06-09 | FORM 8-K | view · |
| S-1 | 2025-05-14 | FORM S-1 | view · |
| 10-Q | 2025-05-12 | FORM 10-Q | view · |
| 8-K | 2025-05-07 | FORM 8-K | view · |
| 8-K | 2025-05-06 | FORM 8-K | view · |
| 8-K | 2025-04-28 | FORM 8-K | view · |
| 10-K | 2025-04-01 | FORM 10-K | view · |
About GNPX
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistant NSCLC, other tumor suppressor genes, and Glioblastoma, which is in preclinical studies. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms al…
Options picks · GNPX
ITM + OTM ideas from the latest scanLoading…
Congress trades · GNPX
STOCK Act disclosuresLoading…
SEC filings & insiders · GNPX
EDGAR · liveLoading…
Holders · GNPX
Institutions & insider activityLoading…